Damora Therapeutics (DMRA) Operating Expenses (2019 - 2026)

Damora Therapeutics (DMRA) has 8 years of Operating Expenses data on file, last reported at $30.8 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 1085.49% year-over-year to $30.8 million; the trailing twelve-month figure through Mar 2026 stood at $239.1 million (up 1150.57% YoY), and the FY2025 full-year result was $210.9 million, up 847.31% from the prior year.
• Operating Expenses for Q1 2026 stood at $30.8 million, down from $201.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $201.7 million in Q4 2025 and bottomed at $2.6 million in Q1 2025.
• The 5-year median for Operating Expenses is $8.6 million (2023), against an average of $21.5 million.
• The widest annual swing landed in 2024, when Operating Expenses plunged 57.45%; it then surged 2739.99% in 2025.
• A 5-year view of Operating Expenses shows it stood at $13.5 million in 2022, then slumped by 50.68% to $6.7 million in 2023, then rose by 6.46% to $7.1 million in 2024, then soared by 2739.99% to $201.7 million in 2025, then plunged by 84.72% to $30.8 million in 2026.
• The last three Operating Expenses figures came in at $30.8 million (Q1 2026), $201.7 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.

Peer Comparison